We scan new podcasts and send you the top 5 insights daily.
Alex says baseline CRP, ferritin and IL-6 help interpret later changes when a patient develops fever, but they are not specific to CRS and should not guide treatment. IL-6 rises after tocilizumab because the receptor is blocked, making subsequent values hard to interpret in practice.
Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.
While prophylactic tocilizumab is used to mitigate CRS with bispecific antibodies in multiple myeloma, this practice should not be applied to lymphoma patients. Rates of high-grade CRS with CD20-bispecifics in lymphoma are low single digits, making routine prophylaxis unnecessary and exposing patients to a drug they likely don't need.
The standard of care for CRS has evolved. Instead of waiting for CRS to escalate, institutions now immediately administer dexamethasone and tocilizumab at the first sign of a fever (grade 1), finding it doesn't harm CAR T-cell expansion and improves safety.
Alex has bispecific patients keep flu and COVID tests at home because fever workup must still rule out infection. In one case, a patient had recurrent CRS fevers and later tested positive for flu B, with cough and congestion distinguishing the infection from her earlier fever-only CRS.
Giving tocilizumab prophylactically before bispecific antibody administration is a key strategy to mitigate Cytokine Release Syndrome. This practice, supported by NCCN guidelines and generally reimbursed, significantly reduces CRS risk, making it safer and more feasible to deliver these therapies in an outpatient setting.
Sepsis is not a monolithic condition. The failure of more than 100 immunomodulatory drug trials is likely because they treated all patients the same. The future of sepsis treatment mirrors oncology: subtyping patients based on their specific inflammatory profile to match them with a targeted therapy.
Circulating biomarkers like hsCRP show general pathway engagement but cannot identify the specific node of inhibition or reflect local tissue inflammation status. Patients routinely exhibit normal systemic hsCRP despite suffering severe inflammation within the cardiac wall, brain, or liver on imaging. As development in sterile neuroinflammation and cardiology advances, drug developers must increasingly rely on imaging rather than blood tests for indication selection and pharmacodynamic proof.
Failures in cardiovascular trials don't invalidate CRP as a biomarker. Like phospho-ERK in oncology, CRP indicates pathway activity, acting as a 'smoke detector'. Success depends on hitting the right upstream target (the 'fire'), not just silencing the downstream signal. Any successful drug will ultimately lower CRP.
Granulocyte colony-stimulating factor (G-CSF) should be temporarily withheld in patients experiencing unresolved cytokine release syndrome. G-CSF administration can independently trigger low-grade fevers and acute inflammatory symptoms, obscuring whether the patient's presentation is an escalating immune toxicity, infection, or standard drug side effect.
Clinicians often conflate bispecific cytokine release syndrome with CAR-T CRS, creating undue reluctance in community settings. Bispecific grade 1 CRS typically presents with mild fevers (around 101°F) that rarely escalate into high-grade fevers (103°F–104°F) seen in CAR-T. In most cases, bispecific grade 1 CRS is safely controlled in the outpatient setting with acetaminophen, ibuprofen, or a single dose of oral dexamethasone.